Success Metrics

Clinical Success Rate
100.0%

Based on 18 completed trials

Completion Rate
100%(18/18)
Active Trials
0(0%)
Results Posted
28%(5 trials)

Phase Distribution

Ph phase_1
1
5%
Ph phase_3
4
18%
Ph phase_4
1
5%
Ph not_applicable
10
45%
Ph phase_2
6
27%

Phase Distribution

1

Early Stage

6

Mid Stage

5

Late Stage

Phase Distribution22 total trials
Phase 1Safety & dosage
1(4.5%)
Phase 2Efficacy & side effects
6(27.3%)
Phase 3Large-scale testing
4(18.2%)
Phase 4Post-market surveillance
1(4.5%)
N/ANon-phased studies
10(45.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.7%

18 of 19 finished

Non-Completion Rate

5.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

22

all time

Status Distribution
Completed(18)
Terminated(1)
Other(3)

Detailed Status

Completed18
unknown3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (4.5%)
Phase 26 (27.3%)
Phase 34 (18.2%)
Phase 41 (4.5%)
N/A10 (45.5%)

Trials by Status

completed1882%
unknown314%
withdrawn15%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT01814527Not Applicable

High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions

Completed
NCT03402789Phase 1

Docosahexaenoic Acid (DHA) Supplementation in Amblyopia

Withdrawn
NCT00000116Phase 3

Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A

Completed
NCT01849250Phase 2

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Completed
NCT01251887Not Applicable

Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition

Completed
NCT02683317Not Applicable

Enteral Administration of Docosahexaenoic Acid to Prevent Retinopathy of Prematurity

Completed
NCT02541929Phase 2

Fish Oil Brain Delivery Study

Completed
NCT01796262Phase 3

The Effects of DHA on Attention Deficit and Hyperactivity Disorder

Completed
NCT04128449Not Applicable

Modifications in the Anaerob Threshold in Cyclists by Consuming Docosahexaenoic Acid (DHA)

Completed
NCT02690857Phase 2

Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)

Completed
NCT02973360Phase 2

Dose-Finding Study of SC411 in Children With Sickle Cell Disease

Unknown
NCT03781557Phase 4

Effects of Omega-3 Fatty Acids Supplement in Cognition of Young Healthy Adults and in Their Reaction Time of Computerized Test After 3 Months of Taking High-concentrated DHA and EPA Fish Softgels

Unknown
NCT03700957Not Applicable

The Impact of Docosahexaenoic Acid on the Prevention of Necrotizing Enterocolitis in Preterm Neonates

Unknown
NCT01976806Phase 2

The Effects of DHA on Periodontitis

Completed
NCT01558193Not Applicable

The Impact of Supplementation With Multi-vitamins/Minerals, With and Without Fatty Acids, on Impulsivity and Aggression

Completed
NCT01049529Phase 2

Effect of Docosahexaenoic Acid on the Inflammatory Response and Clinical Outcomes From Surgical Patients

Completed
NCT00892554Not Applicable

The Effect of Supplemental Docosahexaenoic Acid (DHA) on Neurocognitive Outcomes in Teen and Adult Women With Phenylketonuria(PKU)

Completed
NCT00004827Not Applicable

Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa

Completed
NCT00361374Phase 3

Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression

Completed
NCT00662142Phase 3

Effect of 8-Week Dietary DHA Supplementation on Cerebral Blood Flow and Metabolic Function

Completed

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
22